Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 105, Issue 5, Pages -Publisher
ENDOCRINE SOC
DOI: 10.1210/clinem/dgz277
Keywords
glucocorticoids; adrenal insufficiency; GDF15
Categories
Funding
- University of Cambridge
- University of Cambridge Experimental Medicine Training Initiative (EMI) program
- AstraZeneca
- Swedish Research Council [2015-02561]
- Swedish Federal Government under the LUA/ALF agreement [ALFGBG-719531]
- Medical Research Council [MR/K010271/1, MRC_MC_UU_12012.1]
- Chief Scientist Office [SCAF/17/02]
- Wellcome Trust [107049/Z/15/Z, WT 214274/Z/18/Z]
- British Heart Foundation [RG/11/4/28734]
- National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre
- NIHR Rare Disease Translational Research Collaboration
- Wellcome Trust [107049/Z/15/Z, 214274/Z/18/Z] Funding Source: Wellcome Trust
- MRC [MC_UU_00014/1, MC_UU_12012/1, MC_UU_12012/2, MR/K010271/1, MC_UU_00014/5] Funding Source: UKRI
Ask authors/readers for more resources
Context: GDF15 is a stress-induced hormone acting in the hindbrain that activates neural circuitry involved in establishing aversive responses and reducing food intake and body weight in animal models. Anorexia, weight loss, nausea and vomiting are common manifestations of glucocorticoid deficiency, and we hypothesized that glucocorticoid deficiency may be associated with elevated levels of GDF15. Objective: To determine the impact of primary adrenal insufficiency (PAI) and glucocorticoid replacement on circulating GDF15 levels. Methods and Results: We measured circulating concentrations of GDF15 in a cohort of healthy volunteers and Addison's disease patients following steroid withdrawal. Significantly higher GDF15 (mean +/- standard deviation [SD]) was observed in the Addison's cohort, 739.1 +/- 225.8 pg/mL compared to healthy controls, 497.9 +/- 167.7 pg/mL (P = 0.01). The effect of hydrocortisone replacement on GDF15 was assessed in 3 independent PAI cohorts with classical congenital adrenal hyperplasia or Addison's disease; intravenous hydrocortisone replacement reduced GDF15 in all groups. We examined the response of GDF15 to increasing doses of glucocorticoid replacement in healthy volunteers with pharmacologically mediated cortisol deficiency. A dose-dependent difference in GDF15 (mean +/- SD) was observed between the groups with values of 491.0 +/- 157.7 pg/mL, 427.0 +/- 152.1 pg/mL and 360 +/- 143.1 pg/mL, in the low, medium and high glucocorticoid replacement groups, respectively, P < .0001. Conclusions: GDF15 is increased in states of glucocorticoid deficiency and restored by glucocorticoid replacement. Given the site of action of GDF15 in the hindbrain and its effects on appetite, further study is required to determine the effect of GDF15 in mediating the anorexia and nausea that is a common feature of glucocorticoid deficiency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available